Oncology Articles | Page 2

Montefiore Study May Help Establish Patient Criteria for Proton Therapy
In an effort to build more sophisticated protocols that keep QoL and cost questions at the forefront, Montefiore Einstein Center for Cancer Care and
Albert Einstein College of Medicine’s Institute for Onco-Physics created a mathematical model to identify the optimal candidates for proton therapy, the most modern form of radiation therapy for patients with head and neck cancers.
Nicolas Girad, MD, discusses the importance of evaluating durvalumab in a real-world setting, other questions that remain unanswered in this area, and the role of immunotherapy in patients with non–small cell lung cancer.
Pembrolizumab Misses OS Endpoint in Metastatic TNBC
Single-agent pembrolizumab (Keytruda) did not meet a prespecified endpoint of superior overall survival compared with chemotherapy as a second- or third-line treatment for patients with metastatic triple-negative breast cancer, missing the primary endpoint of the phase III KEYNOTE-119 trial.
Expert Highlights Advances With Locoregional Therapies in HCC
Emil Cohen, MD, discusses the locoregional therapies available for the treatment of patients with hepatocellular carcinoma and offers insight into optimal strategies.
Frontline Afatinib Shows Promise in EGFR+ NSCLC
Antonio Passaro, MD, PhD, discusses findings from a phase IIIb trial for patients with EGFR mutation-positive non–small cell lung cancer and discussed results from other studies investigating ALK and KRAS mutations in patients with NSCLC.
NCCN Goes Global With Guidelines Tailored for Treatment Capabilities Abroad
The NCCN is working to develop modified guidelines for specific regions that offer less-costly and less–technologically intensive cancer treatment alternatives.
Vaibhav Sahai, MBBS, sheds light on ongoing research in metastatic pancreatic cancer and discusses the role of genomic profiling in the space.
Clinical Utility of Tumor Mutational Burden Remains in Flux
Although study findings have identified tumor mutational burden as an important factor in responses to cancer therapy, establishing a definition for expression of this biomarker and harmonizing assays to measure it have proved challenging.
With multiple biomarker-directed clinical trials for metastatic CRC expected to produce data within the next few years, experts in gastrointestinal oncology who took part in a recent OncLive Peer Exchange® program recommended that clinicians become more proactive about incorporating genomic and immune markers into their decision making.
Evidence generated from the randomized study design may be largely ignored by an individual or a community of physicians if the results or strategies being examined do not align with existing beliefs or bias, local practice and referral patterns, and other potentially highly relevant factors unrelated to the trial outcome.
Publication Bottom Border
Border Publication